Samiksha Jaiswal (Editor)

HT 0712

Updated on
Edit
Like
Comment
Share on FacebookTweet on TwitterShare on LinkedInShare on Reddit
ATC code
  
None

CAS Number
  
617720-02-2

ChemSpider
  
8041067

Molar mass
  
393.53 g/mol

Synonyms
  
HT-0712, IPL 455,903

PubChem CID
  
9865375

Formula
  
C25H31NO3

HT-0712

HT-0712, also known as IPL-455903, is an experimental cognitive enhancing drug (nootropic) which is currently undergoing clinical trials. It is currently being licensed by Helicon Therapeutics in San Diego, California. It was originally discovered and tested as part of a preclinical anti-inflammatory program by Inflazyme Pharmaceuticals.

Contents

Mechanism of action

HT-0712 appears to act as a PDE4 inhibitor, thereby increasing cAMP levels. When cAMP levels are increased in neurons, this may trigger activation of cAMP response element-binding proteins (CREB). CREBs are transcription factors involved in the formation of long-term memory.

The side effects of the drug are not yet fully known.

Research

A 2014 study found that HT-0712 significantly boosted memory formation in mice. Data also indicated that HT-0712 may be effective to treat age-associated memory impairment in humans.

References

HT-0712 Wikipedia